Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Medchal, Hyderabad 500078, Telangana, India.
Nanomedicine Research Laboratory, Department of Pharmacy, Birla Institute of Technology & Science-Pilani, Hyderabad Campus, Jawahar Nagar, Medchal, Hyderabad 500078, Telangana, India.
Int J Biol Macromol. 2024 Jan;256(Pt 1):128281. doi: 10.1016/j.ijbiomac.2023.128281. Epub 2023 Nov 20.
Nanomedicines have emerged as a potential strategy to reduce the toxic effect of drugs administered via conventional approaches. Nanomedicines undergo passive and active targeting of the tumor tissues, thereby causing localized drug delivery and reducing drug demand and side effects. Here, we prepared reduction-sensitive oxaliplatin-conjugated human serum albumin nanoparticles with a small size, uniform surfaces, and a satisfactory encapsulation coefficient. The findings of cellular studies demonstrate that utilizing human serum albumin is effective for active tumor targeting. The presence of glutathione-sensitive disulfide linkers in the crosslinking agent and between Pt(IV) and HSA provided dual reduction sensitivity. Cytotoxicity and cell death were enhanced compared to free Oxaliplatin. The outcomes demonstrate that the approach maximized Oxaliplatin's ability to control tumor growth, induced apoptosis, and reduced drug resistance. Therefore, for the first time, our results imply that OXA-SS-HSA NPs were biocompatible, smart, and effective anticancer nanomedicine for triple-negative breast cancer therapy.
纳米药物已成为一种减少通过传统方法给药的药物的毒性作用的潜在策略。纳米药物对肿瘤组织进行被动和主动靶向，从而实现局部药物递送，并减少药物需求和副作用。在这里，我们制备了具有小尺寸、均匀表面和令人满意的包封系数的还原敏感的奥沙利铂偶联人血清白蛋白纳米颗粒。细胞研究结果表明，利用人血清白蛋白可有效进行主动肿瘤靶向。交联剂和 Pt(IV)与人血清白蛋白之间存在谷胱甘肽敏感的二硫键，提供了双重还原敏感性。与游离奥沙利铂相比，细胞毒性和细胞死亡得到增强。结果表明，该方法最大限度地提高了奥沙利铂控制肿瘤生长、诱导细胞凋亡和降低耐药性的能力。因此，我们的结果首次表明，OXA-SS-HSA NPs 是一种具有生物相容性、智能且有效的用于三阴性乳腺癌治疗的抗癌纳米药物。
